Rodriguez-leor, OriolCid-alvarez, Ana BelenLopez-benito, MariaGonzalo, NievesVilalta, VictoriaDiarte De Miguel, Jose AntonioLópez, Leticia FernandezJurado-roman, AlfonsoDiego, AlejandroOteo, Juan FranciscoCuellas, CarlosTrillo, RamiroTravieso, AlejandroAlfonso, FernandoCarrillo, XavierVegas-valle, José MiguelCortes-villar, CarlosPascual, IsaacMuñoz Camacho, Juan FranciscoFlores, XacobeVera-vera, SilvioMoreu, JoseBarreira De Sousa, GillesMartí, DavidJimenez-mazuecos, JesusFuertes, MonicaOcaranza, RaymundoDe La Torre Hernandez, Jose MariaLozano, FernandoSolana Martinez, Santiago G.Gómez-lara, JosepPerez De Prado, ArmandoBenito, TomasEscaned, JavierSánchez, Javier JimenoMoreiras, Javier MartinRivero, BorjaNofrerias, Eduard FernandezLozano, IñigoRoldan, JuanGarcía-touchard, ArturoSerrano, Carlos ArellanoRivero, FernandoAvanzas, PabloAlmendarez, MarcelSantos, Ramon CalviñoEsteban, Pablo PiñonYuskova, MariaRedondo, AlfredoD’ascoli, GiulioMas, Adria TramullasPortero-portaz, Juan J.García-camarero, TamaraMohandes, MohsenRubio, Tomas CantonSuarez, AlfonsoBayón, JeremíasOliveira, Julio PeralSalgado, Carlos AlonsoGómez-hospital, Joan AntoniGonzález, ReyesLópez-minguez, José RamónPalazuelos, JorgeSliwinski, FrankFernandez, Guillermo BastosDe Miguel Castro, Antonio2024-10-142024-10-142024-03-01https://hdl.handle.net/2445/215747BACKGROUND Intravascular lithotripsy (IVL) has demonstrated effectiveness in the treatment of calcified lesions in selected patients with stable coronary disease. OBJECTIVES The authors sought to assess the performance of coronary IVL in calcified coronary lesions in a real-life, all comers, setting. METHODS The REPLICA-EPIC18 study prospectively enrolled consecutive patients treated with IVL in 26 centers in Spain. An independent core laboratory performed the angiographic analysis and event adjudication. The primary effectiveness endpoint assessed procedural success (successful IVL delivery, final diameter stenosis <20%, and absence of in- hospital major adverse cardiovascular events [MACE]). The primary safety endpoint measured freedom from MACE at 30 days. A predefined substudy compared outcomes between acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) patients. RESULTS A total of 426 patients (456 lesions) were included, 63% of the patients presenting with ACS. IVL delivery was successful in 99% of cases. Before IVL, 49% of lesions were considered undilatable. The primary effectiveness endpoint was achieved in 66% of patients, with similar rates among CCS patients (68%) and ACS patients (65%). Likewise, there were no significant differences in angiographic success after IVL between CCS and ACS patients. The rate of MACE at 30 days (primary safety endpoint) was 3% (1% in CCS and 5% in ACS patients [P = 0.073]). CONCLUSIONS Coronary IVL proved to be a feasible and safe procedure in a real-life setting, effectively facilitating stent implantation in severely calcified lesions. Patients with ACS on admission showed similar angiographic success rates but showed a trend toward higher 30-day MACE compared with patients with CCS. (REPLICA-EPIC18 study [Registry of Coronary Lithotripsy in Spain]; NCT04298307) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).application/pdfengcc-by (c) Rodriguez-leor, Oriol et al., 2024http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/article2024-10-03info:eu-repo/semantics/openAccess